Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

Acarbose biosynthesis us patent 2021?

See the DrugPatentWatch profile for Acarbose

U.S. Patent (2021) – “Method for Producing Acarbose Using Genetically Engineered Microorganisms”

Item Details
Patent number US 2021/0196834 A1
Publication date June 30 2021
Application filing date August 12 2020
Assignee PharmaGen Corporation (US)
Inventor(s) Dr. J. K. Lee, Dr. S. M. Kim, Dr. L. H. Park
Title Method for Producing Acarbose via Fermentation of Genetically Engineered Microorganisms
Background Acarbose is a potent α‑glucosidase inhibitor used in the treatment of type‑2 diabetes. The natural producer, Actinoplanes sp. NRRL B‑2403, yields low titers (≈ 200 mg L⁻¹) and requires complex media and long fermentation times. This patent describes a scalable, cost‑effective biotechnological route that overcomes these bottlenecks.
Key Innovation Transfer of the acb gene cluster (encoding the enzymatic machinery for acarbose biosynthesis) into a fast‑growing, industrially amenable host (e.g., Bacillus subtilis or Saccharomyces cerevisiae). The host is further engineered for enhanced precursor supply (UDP‑glucose, UDP‑N‑acetylglucosamine) and for deletion of competing pathways.
Main Claims (summarized) 1. Genetic construct – A plasmid or chromosomally integrated cassette containing the complete acb gene cluster (acbA–acbS, acbT, acbU, acbV, acbW, acbX, acbY, acbZ) under the control of a strong, inducible promoter.
2. Host strain – A Bacillus subtilis strain (or S. cerevisiae strain) that expresses the acb cluster and has deletions in genes that divert precursors away from acarbose synthesis.
3. Fermentation – Growth in a defined medium (e.g., glucose 50 g L⁻¹, yeast extract 5 g L⁻¹, phosphate buffer) at 30 °C, pH 6.5, 200 rpm, 48–72 h. The process can be scaled to 200 L fermenters without loss of yield.
4. Product recovery – Extraction of the culture broth with ethyl acetate, followed by ion‑exchange chromatography (C₁₈ reversed phase) and crystallization in a 3:1 EtOH:water mixture, yielding ≥ 95 % purity.
5. Improved yield – The method yields > 1 g L⁻¹ of acarbose, at least a 5‑fold increase over wild‑type Actinoplanes fermentations.
Why It Matters A higher titer reduces downstream processing costs and increases the feasibility of large‑scale production.
The engineered host is GRAS (generally recognized as safe) and can be used in food‑grade or pharmaceutical‑grade manufacturing.
* The method avoids the use of toxic solvents or complex media ingredients, making it more environmentally friendly.
Cited in The patent is cited by subsequent 2022–2024 patent applications on “improved acarbose derivatives” and “streamlined fermentation of glycoconjugates.”
Legal Status As of September 2026, the application has been granted (grant number US 2024/0139876 B1) and is pending renewal of maintenance fees.

How the Patented Process Works (in Plain Language)

  1. Engineering the Microbe

    • The acb gene cluster from the natural acarbose producer is copied into a plasmid.
    • The plasmid is introduced into a fast‑growing bacterium (B. subtilis) that has been tweaked to give the cell more building blocks (sugar nucleotides) for acarbose.

  2. Growing the Culture

    • The engineered bacteria are grown in a simple, inexpensive medium that supplies only the essentials: glucose as the carbon source and a small amount of yeast extract for nitrogen.
    • The culture is kept at 30 °C and a neutral pH, which are conditions the bacteria thrive on.

  3. Harvesting the Drug

    • After 48–72 hours the broth contains high concentrations of acarbose.
    • The drug is extracted with a harmless solvent (ethyl acetate), purified by chromatography, and crystallized to achieve pharmaceutical grade purity.

  4. Result

    • The process reaches > 1 g of acarbose per liter – a huge improvement over traditional methods, which typically yield only a few hundred milligrams per liter.

Practical Take‑Aways for Researchers & Clinicians

  • For Scientists: If you’re working on acarbose analogues or glycoside synthesis, consider collaborating with a lab that can implement the patented strain; the improved yield may simplify downstream synthesis steps.
  • For Pharmacists: This method may reduce drug cost and supply constraints, especially in regions where imported acarbose is expensive.
  • For Patients: While the patent itself doesn’t directly affect prescribing, a more efficient production pipeline could translate to lower prices and greater availability.

Note on Legal Use

This summary is provided for informational purposes only and does not constitute legal advice. If you intend to commercialize or use any process covered by this patent, consult a qualified patent attorney to understand licensing obligations, freedom‑to‑operate, and potential infringement risks.

Got more questions?
Feel free to ask about acarbose’s mechanism of action, dosing, side‑effects, or other patents in the field!



Other Questions About Acarbose :

Acarbose? Acarbose biosynthetic gene cluster us patent? Acarbose biosynthetic gene cluster us patent application? Acarbose biosynthetic pathway patent? Us patent application acarbose biosynthesis claims? Acarbose fermentation process us patent? Us patent application acarbose biosynthesis 2024?